insights_auto
Why is DMYD-B up ३.१६%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK १.०५
arrow_upward
+३.१६%(+०.०३२) 1D
अक्टोबर १३, १५:३२:०४ GMT+२ · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK १.०३
High
SEK १.०८
Low
SEK १.०१
Mkt. cap
१५.८४ करोड
Avg. vol.
७.९६ लाख
Volume
६.८२ लाख
52-wk high
SEK १७.८८
52-wk low
SEK ०.९०
EPS
-SEK १.७६
Shares outstanding
१३.४० करोड
No. of employees
४२
Open
SEK १.०३
High
SEK १.०८
Low
SEK १.०१
Mkt. cap
१५.८४ करोड
Avg. vol.
७.९६ लाख
Volume
६.८२ लाख
52-wk high
SEK १७.८८
52-wk low
SEK ०.९०
EPS
-SEK १.७६
Shares outstanding
१३.४० करोड
No. of employees
४२
News stories
From web sources and news partners
National Hog Farmer
·
४४ मिनेट पहिले
NYSE owner plans futures for livestock in a bid to challenge CME Group
Business Wire
·
१ घण्टा पहिले
Powerus (Nasdaq: PUSA) Unveils Fully Autonomous Drone Interceptors at AUSA 2026
GlobeNewswire
·
५७ मिनेट पहिले
Primech Holdings (Nasdaq: PMEC) to Present at LD Micro Main
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB